Banyan Biomarkers Inc.
This article was originally published in Start Up
Executive Summary
For acute brain injury patients, the lack of any reliable biological markers makes it nearly impossible to design trials with any precision. Banyan Biomarkers believes it may hold the key to successful development of traumatic brain injury drugs with its diagnostic blood test-based biomarkers for calpain and caspese-enzymes released by dissolving dead and dying brain cells into the blood.
You may also be interested in...
Start-Up Previews (01/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups are "Treating Traumatic Brain Injury," with profiles of Banyan Biomarkers, NeuroPharma AB, and RemeGenix; and "Can Stents Pull Off a Disappearing Act?," with profiles of Amaranth Medical, Bioabsorbable Therapeutics, and TissueGen Plus these Start-Ups Across Health Care: Design Medical, Kythera Biopharmaceuticals and Plethora Solutions.
Treating Traumatic Brain Injury
Past failures guide start-ups that seek to develop drugs for this silent epidemic, but will investors follow?
Start-Up Previews (01/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups are "Treating Traumatic Brain Injury," with profiles of Banyan Biomarkers, NeuroPharma AB, and RemeGenix; and "Can Stents Pull Off a Disappearing Act?," with profiles of Amaranth Medical, Bioabsorbable Therapeutics, and TissueGen Plus these Start-Ups Across Health Care: Design Medical, Kythera Biopharmaceuticals and Plethora Solutions.